Blanken, Maarten O.
,
Frederix, Geert W.
Nibbelke, Elisabeth E.
Koffijberg, Hendrik
Sanders, Elisabeth A. M.
Rovers, Maroeska M.
Bont, Louis
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (920-035-89)
Article History
Received: 12 July 2017
Revised: 7 November 2017
Accepted: 9 November 2017
First Online: 22 November 2017
Change Date: 22 November 2019
Change Type: Correction
Change Date: 22 November 2019
Change Type: Correction
Change Details: The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.
Change Details: The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.
Compliance with ethical standards
:
: LB reports consulting fees from Janssen, Gilead, Okairos, Mabxience, Alios and AIT, during the conduct of the study; MOB reports consulting fees from AbbVie. All other authors have indicated they have no potential conflicts of interest to disclose.LB reports grants for investigator-initiated studies from MedImmune and from AbbVie, including the MAKI trial from which data for this cost-effectiveness study were derived. All other authors have indicated they have no financial relationships relevant to this article to disclose.
: Informed consent was obtained from all individual participants included in the study.